HENDERSON, Nev., Oct. 20, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the signing of a global supply agreement with a market leader in pet healthcare (the "Company").
Through Volition's supply agreement, the Company is engaged as a worldwide provider of the Nu.Q® Vet Cancer Test through its reference laboratory network for cancer indications in animal health.
There are approximately 84 million pet dogs in the United States and just under 50% of dogs will have at least one veterinary care visit per annum which Volition believes will provide an incredible opportunity to screen those senior dogs (over 7 years) and breeds at risk of cancer from 4 years and upwards.
Dr. Tom Butera, Chief Executive Officer of Volition Veterinary Diagnostics Development LLC commented: "The Nu.Q® Vet Cancer Test was developed with the goal of providing an accessible and affordable screening test to aid early detection. This supply agreement is an exciting moment for Volition as we continue to commercialize our Nu.Q® technology within the companion animal healthcare sector and capitalize on what we believe to be significant mass market opportunities. We share the Company's mission of advancing pet healthcare and are delighted to be working with them. Additional information will be shared in the coming months, including estimated dates of test availability."
Volition is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including cancer in both humans and animals. For more information about Volition's Nu.Q® technology go to: www.volition.com
Note to editors:
Findings from a clinical study conducted by Volition and Professor Wilson-Robles and her team at Texas A&M University, peer-reviewed and published in August 2022, showed that:
- Volition's Nu.Q® Vet Cancer Test detected 76% of systemic cancers ( including lymphoma, hemangiosarcoma, and histiocytic sarcoma) at 97% specificity versus control.
Volition is a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy to use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. Early diagnosis and monitoring have the potential not only to prolong the life of patients but also to improve their quality of life. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present.
Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and additional offices in London and Singapore.
The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website addresses are included in this document as an inactive textual references only.
+44 (0)7557 774620
Safe Harbor Statement
Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's estimated market opportunity, Volition's expectations related to the potential benefits under the supply agreement with the Company , the effectiveness of Volition's blood-based diagnostic, prognostic and disease monitoring tests, and Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
Nucleosomics™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.
View original content to download multimedia:https://www.prnewswire.com/news-releases/volition-signs-global-supply-agreement-for-nuq-vet-cancer-test-301654187.html
SOURCE VolitionRx Limited